NOVARTIS

FDA approves Novartis combo therapy for aggressive type of thyroid…

FDA approves Novartis combo therapy for aggressive type of thyroid…

Published 04/05/2018

(Reuters) - The U.S. Food and Drug Administration on Friday approved Novartis AG’s combination therapy to treat an aggressive type of thyroid cancer. The therapy, [more…]

Novartis CEO Narasimhan remakes drugmaker’s leadership as Wyss exits

Novartis CEO Narasimhan remakes drugmaker’s leadership as Wyss exits

Published 12/03/2018

FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File [more…]

Novartis readies to auction U.S. generic pills business: sources

Novartis readies to auction U.S. generic pills business: sources

Published 16/02/2018

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo(Reuters) - Switzerland’s [more…]

Novartis combo therapy for melanoma gets FDA priority review

Novartis combo therapy for melanoma gets FDA priority review

Published 22/12/2017

FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd WiegmannZURICH [more…]

California court says Novartis can be sued over generic drug injuries

California court says Novartis can be sued over generic drug injuries

Published 21/12/2017

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo(Reuters) - California’s [more…]

Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination

Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination

Published 23/10/2017

Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery. [more…]

Novartis posts a win, Roche a flop in skin cancer trials

Novartis posts a win, Roche a flop in skin cancer trials

Published 10/09/2017

Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. [more…]

Novartis names drugs chief as CEO to deliver return to growth

Novartis names drugs chief as CEO to deliver return to growth

Published 04/09/2017

Novartis (NOVN.S) CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth. [more…]

Novartis hopeful for novel heart drug, despite `modest` benefit

Novartis hopeful for novel heart drug, despite `modest` benefit

Published 27/08/2017

Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine's limited benefits. [more…]

Novartis wins European approval for biosimilar version of Roche`s MabThera

Novartis wins European approval for biosimilar version of Roche`s MabThera

Published 19/06/2017

Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche's blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to treat blood cancers and immunological diseases.

[more…]